Search clinical trials for: Lazertinib(G002)

Total 386 results

Yuhan Corporation

Completed

Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

Healthy Adult Volunteers

Korea, Republic of
Yonsei University

Not yet recruiting

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Korea, Republic of
Myung-Ju Ahn

Recruiting

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

NSCLC

Korea, Republic of
Konkuk University Medical Center
Yuhan Corporation

Recruiting

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

Non Small Cell Lung Cancer

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

Healthy

Netherlands
Yuhan Corporation

Approved for marketing

Early Access Program of Lazertinib in Republic of Korea

Lung Cancer
Jin Hyoung Kang

Recruiting

Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

Lung Neoplasms

Korea, Republic of
Janssen Sciences Ireland UC

Completed

Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet

Healthy

Belgium
NVP Healthcare

Completed

Pharmacokinetic Characteristics and Safety After Administration of NVP-2002

Healthy

Korea, Republic of
RedCloud Bio
R&G Pharma Studies Co.,Ltd.

Recruiting

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
Yonsei University

Not yet recruiting

Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy (CHAMELEON)

Non Small Cell Lung Cancer

Korea, Republic of
Tibotec Pharmaceuticals, Ireland

Completed

TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration

Hepatitis C Virus
Yonsei University

Not yet recruiting

Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer)

Non-small Cell Lung Cancer

Korea, Republic of
OliPass Australia Pty Ltd
Novotech (Australia) Pty Limited

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002

Osteoarthritis

Australia
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

Spain, Japan, Korea, Republic of, Taiwan, Netherlands, United States, Italy, Canada, Singapore
Samsung Medical Center

Not yet recruiting

Lazertinib 160mg in EGFR T790M NSCLC

Lung Cancer Stage IV | EGFR T790M

Korea, Republic of
Yonsei University

Not yet recruiting

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)

Non-small Cell Lung Cancer

Korea, Republic of
Avalo Therapeutics, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Non-Eosinophilic Asthma

United States
Capricor Inc.

Completed

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) (HOPE-OLE)

Duchenne Muscular Dystrophy

United States
Capricor Inc.

Completed

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) (HOPE)

Duchenne Muscular Dystrophy | Cardiomyopathy

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

China
Yonsei University

Not yet recruiting

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations (LU21-16)

NSCLC

Korea, Republic of
Aevi Genomic Medicine, LLC, a Cerecor company

Completed

Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury

Acute Lung Injury | ARDS | COVID-19 Pneumonia

United States
Samsung Medical Center

Not yet recruiting

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | EGFR T790M

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

Healthy

Belgium
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
RedCloud Bio
Parexel

Recruiting

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Non-small Cell Lung Cancer

United States
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Laboratoires Genévrier
Institut National de la Santé Et de la Recherche Médicale, France; Hôpital...

Terminated

Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

Burns

France
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)

Healthy | Hepatic Impairment

Germany
Avalo Therapeutics, Inc.

Terminated

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Crohn Disease | Ulcerative Colitis

United States
Pusan National University Hospital
Yuhan Corporation

Not yet recruiting

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Non-small Cell Lung Cancer

Korea, Republic of
Techfields Pharma Co. Ltd

Withdrawn

A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine

Pain, Back | Osteoarthritis of the Lumbar Spine
Neurological Associates of West Los Angeles

Enrolling by invitation

Focused Ultrasound for the Treatment of ADHD Symptoms

ADHD

United States
Jeil Pharmaceutical Co., Ltd.

Completed

The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers

Overactive Bladder(OAB)

Korea, Republic of
Quark Pharmaceuticals

Completed

A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Acute Kidney Injury

United States, Canada, Germany
Janssen Research & Development, LLC

Completed

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Ukraine
HK inno.N Corporation

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients

Mild to Moderate Atopic Dermatitis
Samsung Medical Center

Not yet recruiting

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Non-Small Cell Lung Cancer Metastatic

Korea, Republic of
Novartis Pharmaceuticals

Withdrawn

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Carcinoma, Non-small Cell Lung
Xiangya Hospital of Central South University

Not yet recruiting

Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

Parkinson's Disease

China
Massachusetts General Hospital

Active, not recruiting

Neuromodulation of Mind-Wandering in Depression

Depression

United States
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Vyluma, Inc.
Syneos Health

Active, not recruiting

CHAMP: Study of NVK-002 in Children With Myopia

Myopia

United States, Hungary, Ireland, Netherlands, Spain, United Kingdom
Quark Pharmaceuticals

Completed

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant (ReGIFT)

Delayed Graft Function

United States, Spain, Canada, Australia, Netherlands, Germany, Belgium, France, Argentina, Brazil, Czechia
Sarepta Therapeutics, Inc.
United States Department of Defense

Completed

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Ebola Hemorrhagic Fever

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

Healthy

United States
Quark Pharmaceuticals

Terminated

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Cardiac Surgery

United States, Germany, Spain, Australia, Austria, Canada, New Zealand, United Kingdom, Belgium, Czechia, France
Dr. Joseph Griffin

Completed

Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)

Cerumen Impaction of Both Ears

United States
Quark Pharmaceuticals

Completed

I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

Delayed Graft Function | Other Complication of Kidney Transplant

United States, Spain, Germany, France, Canada

Search clinical trials for: Lazertinib(G002)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations